Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Sofinnova Partners Information
Geographic Data
Address:
City:
State:
Zip:
Country:
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Twitter
Linkedin
Crunchbase
Metrics
2,015,644Website Global Rank
8,743Website Monthly Traffic
Twitter Followers
Description
Sofinnova Partners is a venture capital firm that invests in the life sciences sector, from seed to later-stage. The firm manages over €2 billion of assets dedicated to life science investing and actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact its collective future. It invests in start-ups, early-stage companies, corporate spin-offs, and occasionally turnaround situations with a focus on Life Sciences (Biopharmaceuticals / Biotech, Medical Devices, Industrial Biotechnology). Sofinnova Partners proactively sources deals, takes a lead role, is most often the first institutional investor in Round A financings, and leads its portfolio companies until exit. They sit on the boards of their portfolio companies and play an active role from the formation phase alongside entrepreneurs. It was headquartered in Paris, Ile-de-France in 1972.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 7/2021 | protera | Series A | 0 |
| 3/2009 | Neosens | Series B | 5.3M |
| 2/2008 | Neosens | Venture Round | 3.7M |
| 5/2004 | Addex Therapeutics | Series B | 0 |
| 3/2007 | MXP4 | Series A | 6.5M |
| 5/2009 | MXP4 | Series B | 2.7M |
| 1/2004 | Infra Worlds | Series A | 1.7M |
| 11/2013 | Pixium Vision | Series A | 20.3M |
| 5/2023 | BrightHeart | Seed Round | 2.1M |
| 2/2019 | GenSight Biologics | Post-IPO Equity | 9.1M |
| 9/2022 | Abivax | Post-IPO Equity | 0 |
| 1/2023 | Amolyt Pharma | Series C | 0 |
| 4/2020 | RefleXion Medical | Series D | 0 |
| 7/2009 | EOS (Ethical Oncology Science) | Series A | 17M |
| 1/2008 | CrestaTech | Series A | 5M |
| 1/2005 | CrestaTech | Seed Round | 1.5M |
| 1/2009 | DBV Technologies | Series B | 7.8M |
| 1/2006 | DBV Technologies | Venture Round | 15.1M |
| 1/2013 | ProQR Therapeutics | Seed Round | - |
| 10/2011 | Hookipa Pharma | Series A | 9.6M |
| 3/2018 | Micropep Technologies | Series A | 5M |
| 2/2003 | Avaki | Series A | 4.2M |
| 3/2008 | Laszlo Systems | Series C | 14.6M |
| 4/2006 | Endoart | Series C | 0 |
| 4/2016 | MedDay | Series B | 0 |
| 4/2018 | Crescendo Biologics | Series B | 0 |
| 10/2000 | Ingenium Pharmaceuticals AG | Series B | 44M |
| 12/2021 | DMC Biotechnologies | Series B | 0 |
| 12/2019 | DMC Biotechnologies | Series A | 0 |
| 11/2011 | NuCana BioMed | Series A | 10.5M |
| 12/2022 | EnginZyme | Series B | 22.3M |
| 5/2022 | GFBiochemicals | Series A | 0 |
| 7/2019 | AblaCare | Series A | 11.2M |
| 2/2017 | Zyl | Venture Round | - |
| 12/2018 | Shockwave Medical | Series D | 0 |
| 12/2013 | Crescendo Biologics | Series A | 28.5M |
| 3/2017 | Biotalys | Series B | 0 |
| 12/2007 | Fovea Pharmaceuticals | Series B | 30M |
| 12/2016 | Hookipa Pharma | Series B | 10.7M |
| 1/2002 | Innate Pharma | Series B | 17.8M |
| 4/2004 | Ablynx | Series B | 30M |
| 7/2007 | Inside Secure | Series B | 0 |
| 3/2000 | Innate Pharma | Series A | 4.4M |
| 3/2023 | Noema Pharma | Series B | 0 |
| 3/2023 | Mediar Therapeutics | Series A | 0 |
| 12/2013 | Green Biologics | Series B | 0 |
| 7/2006 | Accent | Venture Round | 13.3M |
| 5/2019 | DNA Script | Series B | 38.5M |
| 1/2009 | Revolt Technology | Series B | 13.1M |
| 2/2008 | Ocera Therapeutics | Series C | 0 |
| 10/2006 | Domain Therapeutics | Series C | 10.4M |
| 11/2003 | Esmertec AG | Series C | 0 |
| 6/2005 | Revolt Technology | Series A | 8.5M |
| 5/2015 | Twenga | Series A | 11M |
| 6/2021 | Borea Therapeutics | Seed Round | - |
| 10/1998 | BoostWorks | Series A | 3M |
| 12/2012 | Flexion Therapeutics | Series B | 20M |
| 4/2008 | Qosmos | Series C | 10.8M |
| 11/2021 | GlycoEra | Series A | 0 |
| 1/2004 | Intransa | Series C | 8M |
| 1/2005 | VoluBill | Series C | 0 |
| 2/2002 | Tak Imaging | Series B | 9.5M |
| 5/2010 | Crocus Technology | Series C | 0 |
| 9/2019 | Inotrem | Series B | 43.1M |
| 10/2004 | Sensitive Object | Series A | 2.5M |
| 7/2021 | Artios Pharma | Series C | 0 |
| 4/2018 | LimFlow SA | Series C | 33.4M |
| 8/2022 | F2G | Private Equity Round | 0 |
| 7/2005 | Filao | Venture Round | 0 |
| 7/2007 | GlycoVaxyn | Series A | 9.5M |
| 6/2019 | Comet Therapeutics | Series A | 28.5M |
| 9/2007 | Purple Labs | Series A | 12.7M |
| 4/2002 | Esmertec AG | Venture Round | 8.8M |
| 7/2021 | protera | Series A | 0 |
| 11/2002 | PhyFlex Networks | Series B | 0 |
| 1/2019 | HighLife | Series B | 36M |
| 4/2013 | Aledia | Series A | 12.8M |
| 7/2021 | Micropep Technologies | Series A | 10.1M |
| 6/2022 | Micropep Technologies | Series A | 0 |
| 2/2002 | Domain Therapeutics | Series A | 2.6M |
| 7/2019 | Biotalys | Series C | 0 |
| 10/2010 | ASSIA | Series D | 20.8M |
| 1/2007 | Movetis | Series A | 63.8M |
| 6/2010 | QuesCom | Venture Round | 0 |
| 7/2020 | Pixium Vision | Post-IPO Equity | 8.3M |
| 1/2003 | Intransa | Series B | 6M |
| 7/2002 | Addex Therapeutics | Series A | 9.9M |
| 4/2020 | Pi-Cardia | Venture Round | 27M |
| 10/2018 | Sitryx Therapeutics | Series A | 30M |
| 9/2017 | Synthace | Series A | 9.9M |
| 9/2017 | DNA Script | Series A | 13.2M |
| 11/2021 | Nitrase Therapeutics | Series A | 0 |
| 5/2020 | HotSpot Therapeutics | Series B | 65M |
| 3/2004 | UPEK | Series A | 20M |
| 3/2020 | Redx Pharma | Post-IPO Equity | 33.6M |
| 9/2002 | Ablynx | Series A | 4.9M |
| 4/2005 | Tak Imaging | Series C | 10M |
| 11/2005 | Fovea Pharmaceuticals | Series A | 24.2M |
| 1/2004 | Tak Imaging | Series C | 16.3M |
| 7/1999 | BoostWorks | Series B | 7M |
| 10/2009 | Flexion Therapeutics | Series A | 33M |
| 7/2022 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series D | 0 |
| 6/2020 | Protera | Series A | 5.6M |
| 2/2013 | MetGen | Venture Round | 2.9M |
| 3/2008 | Mobile Digital Media | Venture Round | 0 |
| 7/2019 | Comet Biorefining | Venture Round | - |
| 1/2015 | Green Biologics | Equity | 42M |
| 8/2004 | Intransa | Series D | 24M |
| 11/2006 | Abionyx Pharma | Series B | 53.5M |
| 12/2007 | Streamezzo | Series C | 22M |
| 1/2005 | Biolipox | Series C | 41M |
| 4/2018 | Inventiva Pharma | Post-IPO Equity | 44.4M |
| 2/2002 | Intransa | Venture Round | 10M |
| 2/2015 | Synthace | Venture Round | 3.4M |
| 11/2006 | CoreValve | Venture Round | 20M |
| 5/2010 | Noxxon Pharma | Series D | 40.7M |
| 10/2009 | Crescendo Biologics | Seed Round | 0 |
| 2/2016 | MISSION Therapeutics | Series C | 86.5M |
| 5/2004 | Domain Therapeutics | Series B | 19.1M |
| 1/2018 | Aledia | Series C | 0 |
| 7/2006 | GlycoVaxyn | Seed Round | - |
| 5/2007 | Noxxon Pharma | Series C | 50.2M |
| 3/2014 | Inotrem | Series A | 25.1M |
| 11/2018 | InCarda Therapeutics | Series B | 42M |
| 4/2018 | Erydel | Series B | 32.4M |
| 5/2014 | Avantium | Series G | 0 |
| 9/2020 | POLYNEURON | Series A | 15.4M |
| 4/2014 | RefleXion Medical | Series A | 11.6M |
| 11/2014 | myTomorrows | Venture Round | 5.6M |
| 10/2020 | GenSight Biologics | Post-IPO Equity | 0 |
| 2/2012 | BioAmber | Series C | 0 |
| 10/2017 | HighLife | Series A | 14.3M |
| 7/2018 | HotSpot Therapeutics | Series A | 45M |
| 4/2014 | Crescendo Biologics | Series A | 3.3M |
| 5/2018 | Biosyntia | Series A | 4.7M |
| 3/2009 | GlycoVaxyn | Series B | 21.4M |
| 10/2011 | Creabilis | Series B | 20M |
| 11/2019 | TISSIUM | Series B | 43.2M |
| 4/2006 | Varioptic | Series C | 0 |
| 6/2015 | Aledia | Series B | 0 |
| 7/2019 | Microphyt | Venture Round | 31.9M |
| 6/2018 | Castle Biosciences | Venture Round | 0 |
| 4/2020 | Nitrase Therapeutics | Series A | 38M |
| 4/2015 | ReCor Medical | Series D | 15M |
| 6/2009 | blueKiwi software | Series B | 0 |
| 1/2008 | TAK imaging | Series C | 16.2M |
| 9/2002 | EnvoyWorldWide | Series C | 4.5M |
| 6/2016 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series B | 33M |
| 1/2003 | Biolipox | Series B | 21M |
| 12/2021 | EndoRon Medical | Seed Round | 5M |
| 9/2006 | Addex Therapeutics | Series C | 0 |
| 3/2008 | Stentys | Series A | 18M |
| 1/2007 | blueKiwi software | Series A | 5.3M |
| 2/2019 | AFYREN | Venture Round | 23.8M |
| 2/2018 | Mainstay Medical | Post-IPO Equity | 37.5M |
| 2/2021 | Mainstay Medical | Private Equity Round | 0 |
| 6/2018 | NodThera | Series A | 40M |
| 10/2021 | Leucid Bio | Series A | 15.9M |
| 7/2021 | Muna Therapeutics | Series A | 0 |
| 7/2022 | Biosyntia | Series B | 11.7M |
| 1/2011 | DBV Technologies | Series C | 25.5M |
| 4/2014 | NuCana | Series B | 0 |
| 5/2019 | CinCor Pharma | Series A | 50M |
| 3/2004 | Varioptic | Series B | 12.2M |
| 10/2003 | Cotherix | Series C | 55M |
| 9/2004 | Innate Pharma | Series C | 0 |
| 5/2009 | Streamezzo | Series D | 5.5M |
| 4/2016 | RefleXion Medical | Series B | 52M |
| 4/2018 | RefleXion Medical | Series C | 100M |
| 2/2016 | Corvidia | Series A | 26M |
| 1/2007 | Sequoia Pharmaceuticals | Series C | 35M |
| 4/2006 | Streamezzo | Series B | 0 |
| 11/2016 | Shockwave Medical | Series C | 45M |
| 4/2018 | EnobraQ | Seed Round | 3.6M |
| 7/2021 | Comet Biorefining | Series C | 0 |
| 7/2010 | Abionyx Pharma | Series C | 0 |
| 6/2021 | Mnemo Therapeutics | Series A | 90M |
| 10/2016 | MD Start | Venture Round | 0 |
| 3/2017 | Comet Biorefining | Venture Round | - |
| 11/2013 | Hookipa Pharma | Series B | 27M |
| 6/2013 | MetGen | Series A | - |
| 6/2021 | Alia Therapeutics | Seed Round | - |
| 6/2016 | DNA Script | Seed Round | 2.8M |
| 3/2007 | CoreValve | Series C | 33M |
| 8/2005 | Abionyx Pharma | Series A | 30.5M |
| 5/2015 | Shockwave Medical | Series B | 40M |
| 12/2017 | Hookipa Pharma | Series C | 0 |
| 11/2020 | Catamaran Bio | Series A | 0 |
| 5/2019 | Twentyeight-Seven Therapeutics | Series A | 15M |
| 11/2003 | Saegis Pharmaceuticals | Series B | 30M |
| 12/2020 | Noema Pharma | Series A | 60M |
| 1/2008 | Inside Secure | Series C | 0 |
| 2/2006 | Lectus Therapeutics | Series A | 14.3M |
| 3/2023 | BioCorteX | Seed Round | 0 |
| 4/2005 | Laszlo Systems | Series B | 6.3M |
| 9/2007 | VoluBill | Series D | 0 |
| 1/2017 | myTomorrows | Venture Round | 10.6M |
| 3/2011 | Omthera Pharmaceuticals | Series B | 33.9M |
| 6/2020 | NodThera | Series B | 55M |
| 9/2016 | IOmx Therapeutics | Series A | 44.6M |
| 10/2021 | IOmx Therapeutics | Series B | 0 |
| 3/2017 | Breath Therapeutics | Series A | 45.9M |
| 4/2018 | Corvidia | Series B | 60M |
| 5/2020 | CorVent Medical | Seed Round | 0 |
| 2/2023 | Abivax | Post-IPO Equity | 0 |
| 10/2021 | CinCor Pharma | Series B | 0 |
| 3/2023 | Chroma Medicine | Series B | 0 |
| 11/2021 | HotSpot Therapeutics | Series C | 0 |
| 2/2010 | Odoo | Series A | 4.1M |
| 10/2021 | Mozart Therapeutics | Series A | 0 |
| 11/2013 | MISSION Therapeutics | Series B | 32.2M |
| 8/2011 | MISSION Therapeutics | Series A | 6M |
| 4/2020 | Pyrowave | Series B | - |
| 1/2021 | Corwave | Series C | 43.2M |
| 7/2018 | Enthera | Seed Round | 4.7M |
| 11/2013 | CelluComp | Seed Round | 3.9M |
| 9/2006 | Qosmos | Series B | 4.1M |
| 6/2021 | AAVantgarde Bio | Seed Round | - |
| 1/2014 | Shockwave Medical | Series A | 12.5M |
| 2/2022 | Elicit Plant | Series A | 18.3M |
| 4/2013 | Auris Medical | Series C | 51M |
| 6/2022 | Moon Surgical | Series A | 31.3M |
| 2/2015 | Comet Biorefining | Venture Round | - |
| 1/2002 | EnvoyWorldWide | Series B | 8M |
| 3/2017 | HotSpot Therapeutics | Seed Round | - |
| 1/2003 | Varioptic | Series A | 2.1M |
| 2/2013 | Entourage Medical Technologies | Venture Round | 3.3M |
| 11/2020 | Myricx Pharma | Seed Round | 5.9M |
| 3/2019 | POLYNEURON | Series A | 22.6M |
| 12/2009 | Sensitive Object | Series B | 6M |
| 10/2021 | Sphere Fluidics | Venture Round | 41.4M |
| 11/2015 | ObsEva | Series B | 58.9M |
| 9/2019 | Inventiva Pharma | Post-IPO Equity | 681.2k |
| 4/2020 | Genespire | Series A | 17.4M |
| 11/2011 | NuCana | Series A | 0 |
| 9/2015 | Asceneuron | Series A | 30.8M |
| 4/2005 | TAK imaging | Series C | 10M |
| 6/2008 | Creabilis | Series A | 31.4M |
| 9/2006 | Oxxius | Series B | 10M |
| 11/2022 | Microphyt | Series B | 0 |
| 6/2005 | Endotis | Series A | 4.9M |
| 5/2014 | Odoo | Series B | 10M |
| 5/2005 | Sefas Innovation | Venture Round | 3.8M |
| 9/2016 | Delinia | Series A | 35M |
| 1/2022 | SafeHeal | Venture Round | 0 |
| 9/2004 | Oxxius | Series A | 2.9M |
| 10/2006 | Wyplay | Series A | 5.1M |
| 8/2008 | mydeco | Series A | 14.5M |
| 6/2007 | PregLem | Series A | 26M |
| 3/2016 | TISSIUM | Series A | 25.5M |
| 2/2020 | Inventiva Pharma | Post-IPO Equity | 16.4M |
| 6/2019 | AFYX Therapeutics | Debt Financing | 13M |
| 7/2010 | Mainstay Medical | Series A | 6.1M |
| 10/2018 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series C | 40M |
| 4/2020 | Epsilen Bio | Seed Round | - |
| 11/2016 | Corwave | Series B | 17.1M |
| 7/2007 | Diatos | Series D | 12.8M |
| 11/2021 | Home Biosciences | Seed | 15M |
| 12/2007 | PregLem | Series B | 32.2M |
| 5/2020 | PinCell s.r.l. | Seed Round | 1.6M |
| 4/2022 | Prometheus Materials | Series A | 8M |
| 8/2021 | TISSIUM | Series C | 59.1M |
| 4/2020 | EnginZyme | Series A | 6.9M |
| 7/2019 | Abivax | Post-IPO Equity | 13.5M |
| 3/2010 | Omthera Pharmaceuticals | Series A | 6.5M |
| 10/2002 | Cobion | Venture Round | 5.9M |
| 4/2013 | MedDay | Series A | 10.5M |
| 8/2006 | Ablynx | Series C | 50M |
| 1/2016 | ENYO Pharma | Series A | 23.9M |
| 8/2000 | BioSpace | Series B | 10M |
| 12/2021 | Meiogenix | Series A | 12.4M |
| 12/2019 | GenSight Biologics | Post-IPO Debt | 16.6M |
| 4/2022 | LimFlow SA | Series D | 0 |
| 9/2010 | Bee Ware | Series B | 5.6M |
| 5/2005 | Bee Ware | Series A | 3.8M |
| 3/2008 | Filao | Venture Round | 0 |
| 12/2007 | Ascendis Pharma | Series A | 25.7M |
| 3/2005 | Sequoia Pharmaceuticals | Series B | 22M |
| 3/2005 | Filao | Venture Round | 4.6M |
| 4/2014 | ProQR Therapeutics | Series A | 57.9M |
| 7/2020 | Enthera | Series A | 0 |
| 3/2016 | CelluComp | Venture Round | 5.3M |
| 1/2006 | Blyk | Series A | 35.4M |
| 3/2018 | SafeHeal | Series A | 7.4M |
| 11/2021 | Synthace | Series C | 35M |
| 7/2020 | MISSION Therapeutics | Venture Round | 15M |
| 1/2007 | Stentys | Seed Round | - |
| 1/2010 | BioAmber | Series A | 0 |
| 9/2013 | Synthace | Seed Round | 2.1M |
| 10/2022 | Mablink Bioscience | Series A | 30.1M |
| 5/2023 | BrightHeart | Seed Round | 0 |
| 5/2023 | TISSIUM | Series D | 0 |
| 5/2023 | Moon Surgical | Series B | 0 |
| 5/2023 | Werewool | Seed Round | 0 |
| 4/2023 | Alia Therapeutics | Seed Round | 0 |
| 3/2023 | BioCorteX | Seed Round | 0 |
| 3/2023 | deepc | Series A | 0 |
| 3/2023 | Kiro | Series A | 0 |
| 3/2023 | Mediar Therapeutics | Series A | 0 |
| 3/2023 | Noema Pharma | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
